Arizona-based Axolotl Biologix, an innovative leader in regenerative medicine, is proud to announce that Dr. Richard Silverstein, DPM, a board-certified podiatry specialist, has agreed to be a founding member of the company’s newly formed Medical Advisory Board.

Among his responsibilities as Medical Advisory Board member, Dr. Silverstein will be conducting clinical trials on the effectiveness of AxoBioFluid® A, a human liquid allograft derived from the amniotic components of the placenta to advance soft tissue repair, replacement and reconstruction. Clinical applications include osteoarthritis, joint pain, inflammatory conditions such as bursitis, tendonitis and fasciitis, and soft tissue injuries such as ligament and tendon sprains, muscle tears and wound care.

Dr. Silverstein serves as the Division Head of the Podiatry Section, Department of Surgery at Harford Memorial Hospital and is board-certified by the American Board of Podiatric Surgery. He opened his private practice in Havre de Grace in 2000, has had numerous works published and frequently lectures at hospitals and local community organizations.

“Dr. Silverstein is a trusted podiatry specialist who will add tremendous value to our new Medical Advisory Board,” said AxolotlBiologix President, Phillip Larson. “We look forward to seeing his clinical evaluations using AxoBioFluid®A to help patients experiencing feet and ankle joint problems.”

“Axolotl Biologix is dedicated to advancing the evolving field of regenerative medicine,” said Dr. Silverstein. “I am honored to be on the company’s advisory board with a team of highly esteemed physicians interested in innovative solutions that can help my patients in Havre de Grace reduce inflammation and speed up recovery times.“

Dr. Silverstein is well known in Havre de Grace and will begin clinical trials at Union Foot Care. He has been serving patients for 20-years, receiving his medical training at the William M. Scholl College of Podiatric Medicine in Chicago, and completing his surgical residency training at Sinai Hospital of Baltimore. Dr. Silverstein graduated from Syracuse University with a Bachelor of Science in biology.

About Axolotl Biologix:

Axolotl Biologix, Inc. is an innovative biotechnology leader in regenerative medicine through research, technology and clinical application. Axolotl Biologix is expanding the human body’s ability to regenerate by developing and manufacturing regenerative human cell and tissue medical technologies that are disrupting traditional, more invasive, painful and expensive treatment protocols. For more information, visit www.axobio.com